Breast-cancer patients carrying two well-known genes linked to the disease have the same survival chances as noncarriers of the genes who develop the disease, according to a study by Israeli and Canadian researchers.
The study was aimed in part at shedding light on whether breast-cancer treatment should be tailored differently for women with the two gene mutations, known as BRCA1 and BRCA2. The results provided no decisive answers on that question, but could provide some comfort to carriers who might feel the odds stacked against them.
Leave a Reply